Kassie Tadele Derbew, Yimenu Bayu Wondimneh, Baye Temesgen Gelagey, Shimelash Rahel Asres, Abneh Aysheshim Asnake
Department of Public Health, College of Health Science, Debre Markos University, Debre Markos, Ethiopia.
Biomedical Department, College of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Front Med (Lausanne). 2025 Apr 16;12:1485676. doi: 10.3389/fmed.2025.1485676. eCollection 2025.
Cancer is a disease characterized by uncontrolled cell growth that can invade and spread to other body parts. Drugs used for chemotherapy can cause damage to non-cancer cells and lead to a low blood cell count. There are controversial findings regarding the differences in the counts of blood cell types. Studies on the counts of blood cell types before and after chemotherapy are limited. Therefore, this study aimed to address this gap.
A retrospective study was conducted on 354 patients from 1 September 2022 to 1 October 2022 to compare blood cell type profiles in pre-and post-operative periods. A chi-squared test and paired -test were performed to analyze the data.
Data were collected from 354 patients. The mean age of the respondents was 41.26 (±16.67) years. At the initial diagnosis, 167 patients (47%) were categorized as having stage III cancer, while 159 patients were categorized as having stage IV cancer. Before and after chemotherapy the mean heamoglobin level is 12.95 g/dL and 12.30 g/ dL respectively and the prevalence of anemia among cancer patients before chemotherapy and after chemotherapy was 25.14% (95%:20.88, 29.94) and 35.54% (95%: 30.75; 40.73), respectively. The mean value of neutrophils before and after chemotherapy was 52.72 and 50.82%, respectively. The frequency of neutropenia among cancer patients was 22.32% (95% 18.26; 26.96) before chemotherapy and 27.97% (95%:23.52; 32.88) after chemotherapy, and the mean value of lymphocytes before and after chemotherapy was 37.50 and 34.29%, respectively. Lymphopenia among the study participants was 16.38% (95%:12.87; 20.62) before chemotherapy and 17.51% (95%13.88, 21.84) after chemotherapy. Among patients with stomach, rectal, and bone cancers, there was no significant difference in the counts of all blood cell types before and after chemotherapy. The mean reduction in platelets was 23. 51 × 10cells/mm ( = 0.001). For red blood cells (RBCs), the mean decrease was 0.63 × 10cells/mm ( = 0.08), and for white blood cells (WBCs), it was 2.49 × 10 cells/mm ( = 0.012).
After chemotherapy, all hematological parameters showed a decrease, indicating that chemotherapy significant impacted the levels of these hematological parameters. Therefore, replacement therapy should be considered after chemotherapy.
癌症是一种以细胞不受控制地生长为特征的疾病，可侵袭并扩散至身体其他部位。用于化疗的药物会对非癌细胞造成损害，并导致血细胞计数降低。关于血细胞类型计数的差异存在有争议的研究结果。化疗前后血细胞类型计数的研究有限。因此，本研究旨在填补这一空白。
对2022年9月1日至2022年10月1日期间的354例患者进行回顾性研究，以比较术前和术后的血细胞类型谱。采用卡方检验和配对检验对数据进行分析。
收集了354例患者的数据。受访者的平均年龄为41.26（±16.67）岁。在初次诊断时，167例患者（47%）被归类为III期癌症，而159例患者被归类为IV期癌症。化疗前后血红蛋白平均水平分别为12.95 g/dL和12.30 g/dL，化疗前和化疗后癌症患者贫血患病率分别为25.14%（95%：20.88，29.94）和35.54%（95%：30.75；40.73）。化疗前后中性粒细胞的平均值分别为52.72%和50.82%。癌症患者化疗前中性粒细胞减少症的发生率为22.32%（95% 18.26；26.96），化疗后为27.97%（95%：23.52；32.88），化疗前后淋巴细胞的平均值分别为37.50%和34.29%。研究参与者化疗前淋巴细胞减少症的发生率为16.38%（95%：12.87；20.62），化疗后为17.51%（95% 13.88，21.84）。在患有胃癌、直肠癌和骨癌的患者中，化疗前后所有血细胞类型的计数没有显著差异。血小板的平均减少量为23.51×10⁹细胞/mm³（P = 0.001）。对于红细胞（RBC），平均减少量为0.63×10¹²细胞/mm³（P = 0.08），对于白细胞（WBC），为2.49×10⁹细胞/mm³（P = 0.012）。
化疗后，所有血液学参数均显示下降，表明化疗对这些血液学参数水平有显著影响。因此，化疗后应考虑替代疗法。
